PL401502A1 - Epitop i jego zastosowanie - Google Patents

Epitop i jego zastosowanie

Info

Publication number
PL401502A1
PL401502A1 PL40150212A PL40150212A PL401502A1 PL 401502 A1 PL401502 A1 PL 401502A1 PL 40150212 A PL40150212 A PL 40150212A PL 40150212 A PL40150212 A PL 40150212A PL 401502 A1 PL401502 A1 PL 401502A1
Authority
PL
Poland
Prior art keywords
common epitope
epitope
application
enterobacterial
vaccines
Prior art date
Application number
PL40150212A
Other languages
English (en)
Other versions
PL220297B1 (pl
Inventor
Anna Ewelina Jarząb
Danuta Witkowska
Edmund Ziomek
Andrzej Gamian
Original Assignee
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością filed Critical Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL401502A priority Critical patent/PL220297B1/pl
Priority to PCT/PL2013/050026 priority patent/WO2014073998A1/en
Priority to US14/441,248 priority patent/US9890194B2/en
Publication of PL401502A1 publication Critical patent/PL401502A1/pl
Publication of PL220297B1 publication Critical patent/PL220297B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem wynalazku jest wyizolowane białko zawierające wspólny epitop rozpoznawany przez przeciwciała krwi pępowinowej o swoistości anty enterobakteryjnej, występujące w ekstrakcie bakteryjnych białek błony zewnętrznej oraz jego fragmenty zawierające ten wspólny epitop, nadające się do stosowania w medycynie i farmacji, zwłaszcza do produkcji szczepionek i testów diagnostycznych oraz materiałów powinowactwa.
PL401502A 2012-11-07 2012-11-07 Epitop i jego zastosowanie PL220297B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL401502A PL220297B1 (pl) 2012-11-07 2012-11-07 Epitop i jego zastosowanie
PCT/PL2013/050026 WO2014073998A1 (en) 2012-11-07 2013-11-07 An epitope and its use
US14/441,248 US9890194B2 (en) 2012-11-07 2013-11-07 Epitope and its use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL401502A PL220297B1 (pl) 2012-11-07 2012-11-07 Epitop i jego zastosowanie

Publications (2)

Publication Number Publication Date
PL401502A1 true PL401502A1 (pl) 2014-05-12
PL220297B1 PL220297B1 (pl) 2015-10-30

Family

ID=49876951

Family Applications (1)

Application Number Title Priority Date Filing Date
PL401502A PL220297B1 (pl) 2012-11-07 2012-11-07 Epitop i jego zastosowanie

Country Status (3)

Country Link
US (1) US9890194B2 (pl)
PL (1) PL220297B1 (pl)
WO (1) WO2014073998A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL235826B1 (pl) * 2014-07-22 2020-11-02 Wroclawskie Centrum Badan Eit Spolka Z Ograniczona Odpowiedzialnoscia Immunogenny koniugat i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez pałeczki jelitowe z rodziny Enterobacteriaceae
US9871794B2 (en) * 2015-12-14 2018-01-16 Neustar, Inc. Domain name system and method of operating using restricted channels

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US20090144849A1 (en) * 2002-02-11 2009-06-04 Lutfiyya Linda L Nucleic acid molecules and other molecules associated with transcription in plants
US20100069293A1 (en) * 2002-02-27 2010-03-18 Pharmain Corporation Polymeric carrier compositions for delivery of active agents, methods of making and using the same
US7105347B2 (en) * 2002-07-30 2006-09-12 Corning Incorporated Method and device for protein delivery into cells
EP2168986A3 (en) * 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
ES2362301T3 (es) * 2005-03-03 2011-07-01 Revance Therapeutics, Inc. Composiciones y procedimientos para aplicaciones tópicas y liberación transdérmica de un oligopéptido.
JP5116663B2 (ja) * 2005-04-15 2013-01-09 アリゾナ バイオメディカル リサーチ コミッション 転移癌の処置のための治療用ペプチド
US20100047170A1 (en) * 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
PL380105A1 (pl) 2006-07-04 2008-01-07 Instytut Immunologii I Terapii Doświadczalnej Im. L. Hirszfelda Pan Białko, jego fragment oraz ich zastosowania
US8974776B2 (en) * 2007-05-14 2015-03-10 Covidien Lp Biodegradable peptide releasing polymers
US20110038888A1 (en) * 2008-01-10 2011-02-17 Peter Emtage Adjuvant compositions comprising poly-ic and a cationic polymer
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2011119484A1 (en) * 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
EP2771349B1 (en) * 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding

Also Published As

Publication number Publication date
WO2014073998A1 (en) 2014-05-15
US9890194B2 (en) 2018-02-13
PL220297B1 (pl) 2015-10-30
US20160024150A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
CY1121934T1 (el) Αντισωματα anti-fcrn
Ferreira et al. Targeting human pathogenic bacteria by siderophores: a proteomics review
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
BR112014026755A2 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
GT201200271A (es) Proteínas que se unen al tnf-a
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
BR112015012014A2 (pt) proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
MX394993B (es) Polipéptidos efectores de la subunidad a de la toxina shiga desinmunizada para aplicaciones en mamíferos.
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
AR092662A1 (es) Anticuerpos anti-ddr1
MX2015009594A (es) Construcciones de anticuerpos para cdh19 y cd3.
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
EA201401065A1 (ru) Ang2-связывающие молекулы
BR112016004324A2 (pt) anticorpos
BR112016017986A2 (pt) anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos de produção de um anticorpo, de tratamento do câncer, de tratamento de uma doença e de detecção de jagged1 humana em uma amostra biológica, imunoconjugado, formulação farmacêutica e uso do anticorpo
HK1210714A1 (en) Antibody formulations and uses thereof
MX394233B (es) Anticuerpo específico contra e. coli mdr.
MX378905B (es) Pestivirus.
MX383506B (es) Parvovirus porcino.
MX385451B (es) Proteínas sintéticas autoensamblables.
AR087654A1 (es) METODO DIAGNOSTICO DE ANIMALES VACUNADOS CON PESTIVIRUS QUIMERICO EN EL CUAL LA PROTEINA Eʳⁿˢ DEL VIRUS DE LA DIARREA VIRAL BOVINA (BVDV) ES REMPLAZADA POR PROTEINA Eʳⁿˢ DE PESTIVIRUS DE ANTILOPE AMERICANO
WO2014085821A3 (en) Fully human antibodies and fragments recognizing human c-met
MX2012005595A (es) Proteina marcadora para diabetes de tipo 2.
PL404498A1 (pl) Test diagnostyczny zakażeń Streptococcus agalactiae
AR091980A1 (es) Cepas mutantes de neospora y sus usos